CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 439 filers reported holding CRISPR THERAPEUTICS AG in Q2 2022. The put-call ratio across all filers is 1.02 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $1,081,000 | -35.8% | 17,783 | +18.1% | 0.07% | -28.2% |
| Q3 2021 | $1,685,000 | -21.9% | 15,053 | +13.0% | 0.10% | -23.1% |
| Q2 2021 | $2,158,000 | -18.0% | 13,327 | -22.4% | 0.13% | -25.1% |
| Q4 2020 | $2,631,000 | +101.1% | 17,183 | +9.8% | 0.18% | +82.7% |
| Q3 2020 | $1,308,000 | +58.9% | 15,644 | +39.7% | 0.10% | +27.3% |
| Q2 2020 | $823,000 | +103.2% | 11,198 | +17.3% | 0.08% | +63.8% |
| Q1 2020 | $405,000 | +6.0% | 9,546 | +17.8% | 0.05% | +46.9% |
| Q2 2019 | $382,000 | +75.2% | 8,105 | +6.4% | 0.03% | +52.4% |
| Q4 2018 | $218,000 | – | 7,620 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $31,294,000 | 31.24% |
| NEA Management Company, LLC | 1,590,002 | $365,593,000 | 10.56% |
| Ariose Capital Management Ltd | 37,900 | $2,379,000 | 9.30% |
| ARK Investment Management | 9,404,071 | $590,294,000 | 2.46% |
| NIA IMPACT ADVISORS, LLC | 80,082 | $5,027,000 | 2.44% |
| Nikko Asset Management Americas, Inc. | 4,619,747 | $291,044,000 | 2.14% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,139,000 | 1.98% |
| Integral Health Asset Management, LLC | 120,000 | $7,532,000 | 1.96% |
| Valiant Capital Management, L.P. | 240,683 | $15,108,000 | 1.73% |
| Deuterium Capital Management, LLC | 18,000 | $1,130,000 | 1.45% |